The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2018 | Novel therapies on the horizon for cutaneous T-cell lymphoma
Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses new therapy options for cutaneous T-cell lymphoma, including brentuximab vedotin and mogamulizumab. In addition, Prof. Stadler discusses promising targets for therapeutic antibodies.
